X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-baricitinib-tablets-76712.pdf
https://endpts.com/eli-lillys-alopecia-drug-olumiant-off-to-positive-start-with-doctors-spherix-research-finds/
https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/
https://www.europeanpharmaceuticalreview.com/news/175849/jak-inhibitors-unsafe-for-cardiovascular-cancer-risk-prac/
https://endpts.com/ema-limits-use-of-jak-inhibitors-for-at-risk-groups-in-wake-of-safety-concerns/
https://endpts.com/fda-loosens-marketing-rules-for-authorized-covid-drugs-but-will-it-move-the-needle/
https://www.pharmatimes.com/news/eli_lilly_receives_marketing_authorisation_for_baricitinib_1456284
https://www.europeanpharmaceuticalreview.com/news/173574/trio-of-therapies-reduces-risk-of-death-in-patients-with-severe-covid-19/
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-baricitinib-tablets-1659342715.pdf
https://www.fiercepharma.com/pharma/eli-lillys-olumiant-snags-first-fda-green-light-alopecia-areata
https://www.fiercepharma.com/pharma/ema-signs-nine-drugs-including-sanofis-xenpozyme-and-lillys-olumiant-alopecia-areata
https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-lilly-and-incytes-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata-aa-301551999.html
https://www.fiercepharma.com/pharma/fda-converts-eua-lillys-olumiant-full-nod-hospitalized-covid-19-patients
https://www.expresspharma.in/us-fda-approves-lilly-and-incytes-olumiant-for-treating-certain-hospitalised-patients-with-covid-19/
https://health.economictimes.indiatimes.com/news/pharma/uk-health-service-rolls-out-arthritis-drug-baricitinib-to-treat-covid/91356182
https://www.prnewswire.com/news-releases/nearly-40-of-adults-with-alopecia-areata-taking-olumiant-4-mg-saw-at-least-80-scalp-hair-coverage-at-52-weeks-in-lillys-pivotal-phase-3-studies-301510503.html
https://www.reuters.com/business/healthcare-pharmaceuticals/arthritis-drug-shown-reduce-risk-covid-death-large-uk-trial-2022-03-03/
https://endpts.com/ema-initiates-safety-review-on-jak-inhibitors-galapagos-woes-continue-as-it-terminates-latest-study/
https://www.worldpharmanews.com/research/5940-computer-predicted-life-saving-benefit-of-baricitinib-for-ventilated-covid-patients
https://www.fiercepharma.com/pharma/eli-lilly-incyte-axe-olumiant-lupus-amid-eczema-stalemate-at-fda
https://www.pharmaceutical-technology.com/news/who-recommends-covid-drugs/
https://www.fiercepharma.com/marketing/abbvie-s-rinvoq-pfizer-s-xeljanz-slapped-fda-warnings-as-jak-safety-clamp-down-unfolds
https://www.prnewswire.com/news-releases/olumiant-long-term-safety-profile-established-up-to-9-3-years-in-integrated-analysis-of-more-than-3-700-patients-with-rheumatoid-arthritis-301419288.html
https://www.prnewswire.com/news-releases/olumiant-significantly-improved-hair-regrowth-to-at-least-80-scalp-coverage-as-early-as-24-weeks-across-first-completed-phase-3-studies-for-alopecia-areata-301388398.html
https://www.clinicaltrialsarena.com/features/jak-inhibitors-atopic-dermatitis/
https://timesofindia.indiatimes.com/world/us/us-fda-allows-lillys-covid-19-drug-to-be-taken-without-remdesivir/articleshow/84862822.cms
https://www.fiercepharma.com/marketing/incyte-latest-to-fall-victim-to-jak-scrutiny-as-fda-pushes-back-jakafi-review-gvhd
https://www.pharmacompass.com/pdf/news/natco-signs-voluntary-licensing-agreement-with-lilly-for-baricitinib-for-covid-19-in-india-1623748356.pdf
https://www.thehindubusinessline.com/news/lilly-signs-two-pacts-with-msn-labs-and-torrent-pharma-for-covid-drug/article34548884.ece
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-inks-licensing-pact-with-eli-lilly-for-covid-19-treatment-drug/articleshow/82557079.cms
https://www.pharmacompass.com/pdf/news/natco-receives-emergency-use-approval-for-baricitinib-tablets-for-covid-19-1623748026.pdf
https://investor.lilly.com/news-releases/news-release-details/lilly-accelerating-baricitinibs-availability-india-following
https://www.ema.europa.eu/en/news/ema-starts-evaluating-use-olumiant-hospitalised-covid-19-patients-requiring-supplemental-oxygen
https://www.fiercepharma.com/pharma/lilly-armed-new-data-to-seek-first-class-approval-for-olumiant-alopecia
https://www.biopharmadive.com/news/eli-lilly-baricitinib-alopecia-areata-results/598791/
https://www.prnewswire.com/news-releases/olumiant-showed-significant-improvements-in-the-severity-and-extent-of-atopic-dermatitis-and-other-patient-reported-outcomes-in-phase-3-study-analyses-301275620.html
https://www.prnewswire.com/news-releases/lilly-and-incytes-baricitinib-improved-hair-regrowth-for-alopecia-areata-patients-in-second-phase-3-study-301272086.html
https://www.prnewswire.com/news-releases/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients-301264421.html
https://www.prnewswire.com/news-releases/lilly-and-incyte-communicate-review-extension-of-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301263386.html
https://www.fiercebiotech.com/research/ai-uncovers-eli-lilly-s-rheumatoid-arthritis-drug-olumiant-as-potential-alzheimer-s
https://www.prnewswire.com/news-releases/baricitinib-is-first-jak-inhibitor-to-demonstrate-hair-regrowth-in-phase-3-alopecia-areata-aa-trial-301239291.html
https://www.prnewswire.com/news-releases/data-from-actt-2-trial-of-baricitinib-in-hospitalized-covid-19-patients-supportive-of-the-eua-published-in-new-england-journal-of-medicine-301191422.html
https://www.nih.gov/news-events/news-releases/baricitinib-plus-remdesivir-shows-promise-treating-covid-19#:~:text=In%20the%20study%2C%20the%20combination,eight%20days%20to%20seven%20days.
https://www.europeanpharmaceuticalreview.com/news/134632/trial-to-compare-dexamethasone-and-baricitinib-in-hospitalised-covid-19-patients/
https://www.fiercepharma.com/pharma/lilly-scores-fda-emergency-authorization-for-olumiant-covid-19-its-second-therapeutic-option
https://endpts.com/eli-lilly-picks-up-another-covid-19-eua-as-regulators-wave-through-its-olumiant-plus-remdesivir-combo/
https://seekingalpha.com/news/3638211-eli-lilly-arthritis-drug-gets-fda-ok-for-emergency-use-to-treat-covidminus-19
Market Place
Share 
